A phase Ib study testing anti-TIM-3 antibody (MBG453) in combination with decitabine for patients with high-risk MDS and AML reported that 9 of 31 (29%) patients with AML achieved partial response or better response and eight (25.8%) additional patients showed more than a 50% reduction in marrow blasts [122]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.